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Abstract
Background: Consensus is lacking regarding the optimal salvage therapy for patients 
with follicular lymphoma who relapse after or are refractory to immunochemotherapy.
Methods: This phase II trial evaluated the efficacy and safety of response‐adapted 
therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD) 
in follicular lymphoma patients who relapsed after or were refractory to first‐line 
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1 |  INTRODUCTION
Follicular lymphoma (FL) is the most common form of in-
dolent lymphoma and the second most frequent subtype of 
non‐Hodgkin's lymphoma (NHL) diagnosed in the Western 
hemisphere.1,2 Rituximab plus chemotherapy has signifi-
cantly improved outcomes in patients with newly diagnosed 
FL and emerged as the standard of care for frontline therapy.3-7 
Rituximab maintenance after induction therapy has signifi-
cantly improved progression‐free survival (PFS) in FL patients.8 
Although FL usually responds to first‐line immunotherapy or 
immunochemotherapy, the majority of patients relapse.
In the absence of consensus regarding optimal salvage ther-
apy, the selection of treatment for relapsed FL poses a daunt-
ing challenge. Moreover, there are limited treatment options 
for patients with refractory FL. Multiple factors influence the 
choice of salvage treatment, including prior treatment, du-
ration of prior response, age, comorbidities, and therapeutic 
goals.2 When this trial was designed recommended treatment 
options included fludarabine‐based regimens combined with 
rituximab9 and R‐CHOP (rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone).10,11
Two phase II trials of bendamustine plus rituximab (BR) 
as salvage therapy in indolent lymphoma patients reported 
overall response rates (ORR) in FL subgroups of 93%12 and 
96%13 (median PFS, 23 and 24 months, respectively). In a 
German prospective randomized phase III trial, BR was more 
effective than fludarabine plus rituximab (FR) in patients 
with relapsed indolent lymphoma.14
Survival is poor in treatment‐refractory FL patients and 
those with early progression after first‐line therapy,15-17 
particularly in those previously treated with rituximab.18 A 
phase II trial of the combination of bendamustine, mitoxan-
trone, and rituximab found that it was effective (ORR, 92%; 
median PFS, 19 months) and well‐tolerated in patients with 
relapsed/refractory indolent lymphoma with or without prior 
rituximab‐containing immunochemotherapy.19
While rituximab maintenance has shown beneficial ef-
fects in relapsed patients not previously exposed to rituximab 
in first‐line therapy,10 few studies have evaluated rituximab 
maintenance at the moment of relapse in patients previously 
exposed to rituximab in first‐line therapy,10,14 and available 
information on the usefulness of second rituximab mainte-
nance therapy is anecdotal.20 Data on the effect of rituximab 
immunochemotherapy. Sixty patients received three treatment cycles, and depend-
ing on their response received an additional one (complete/unconfirmed complete 
response) or three (partial response) cycles. Patients who responded to induction re-
ceived rituximab maintenance therapy for 2 years.
Results: Thirty‐three (55%) and 42 (70%) patients achieved complete/unconfirmed 
complete response after three cycles and on completing induction therapy (4‐6 cy-
cles), respectively (final overall response rate, 88.3%). Median progression‐free sur-
vival was 56.4 months (median follow‐up, 28.3 months; 95% CI, 15.6‐51.2). Overall 
survival was not reached. Progression‐free survival did not differ between patients 
who received four vs six cycles (P = .6665), nor between patients who did/did not 
receive rituximab maintenance after first‐line therapy (P = .5790). Median progres-
sion‐free survival in the 10 refractory patients was 25.5 months (95% CI, 0.6‐N/A) 
and was longer in patients who had shown progression of disease after 24 months 
of first‐line therapy (median, 56.4  months; 95% CI, 19.8‐56.4) than in those who 
showed early progression (median, 42.31 months; 95% CI, 24.41–NA) (P = .4258). 
Thirty‐six (60%) patients had grade 3/4 neutropenia. Grade 3/4 febrile neutropenia 
and infection were recorded during induction (4/60 [6.7%] and 5/60 [8.3%] patients, 
respectively) and maintenance (2/43 [4.5%] and 4/43 [9.1%] patients, respectively).
Conclusions: This response‐adapted treatment with RBMD followed by rituximab 
maintenance is an effective and well‐tolerated salvage treatment for relapsed/refrac-
tory follicular lymphoma following first‐line immunochemotherapy.
Clinical trial registration: ClinicalTrials.gov # NCT01133158.
K E Y W O R D S
bendamustine, follicular lymphoma, immunochemotherapy, refractory, relapsed
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maintenance after treatment with BR in patients with re-
lapsed/refractory indolent lymphoma are limited to the find-
ings of a phase III trial in which a small subgroup of patients 
(two thirds of cases were rituximab‐naïve) received ritux-
imab maintenance after responding to BR.14 Obinutuzumab 
plus bendamustine followed by obinutuzumab maintenance 
has shown clinically beneficial effects in rituximab‐refrac-
tory patients with indolent NHL.18
In this phase II trial, we evaluated the efficacy and safety 
of salvage therapy with RBMD followed by rituximab main-
tenance in patients with relapsed/refractory FL after first‐line 
rituximab‐based immunochemotherapy.
2 |  MATERIALS AND METHODS
2.1 | Study design and patient eligibility
RBMDGELTAMO08 is a multicenter, phase II trial con-
ducted at 27 Spanish centers by GELTAMO (The Spanish 
Lymphoma Cooperative Group).
The study population consisted of patients who had re-
lapsed after or were refractory to first‐line rituximab‐based 
immunochemotherapy, including those who had received 
rituximab maintenance after first‐line therapy. Patients el-
igible for inclusion were those aged 18‐75  years who had 
been previously diagnosed (lymph node or tissue biopsy) by 
a local pathologist and fulfilled the following criteria: FL 
grade, 1‐3a; Eastern Cooperative Oncology Group (ECOG) 
score, ≤2; Ann Arbor stage, I–IV; Follicular Lymphoma 
International Prognostic Index (FLIPI), 0‐5. Patients to 
whom any of the following exclusion criteria applied were 
considered ineligible: previous radiotherapy treatment; re-
lapse after autologous stem cell transplantation; central ner-
vous system involvement; previous or concomitant malignant 
disease; clinical suspicion or histological confirmation of 
transformed lymphoma (in the staging bone marrow biopsy 
performed on each patient or in a new lymph node or tissue 
biopsy performed prior to inclusion in some patients with 
clinical suspicion of transformation); previous or active in-
fection with hepatitis B virus, hepatitis C virus, or HIV; other 
serious immunosuppressive conditions; organ function defi-
cits (liver, kidney, or heart) unrelated to lymphoma.
Refractory patients were defined as those who were nonre-
sponsive (less than partial response) or showed disease progres-
sion after at least three immunochemotherapy cycles, during 
rituximab maintenance, or within less than 6 months of the last 
immunochemotherapy cycle or the last dose of rituximab main-
tenance therapy. Relapse was defined as progressive disease 
beyond 6 months after the last cycle of first‐line immunoche-
motherapy or the last dose of rituximab maintenance therapy.
The trial was approved by the Institutional Review Boards 
and the local ethical committees of each participating center. 
Patients provided written informed consent before inclusion. 
All procedures were performed according to the principles 
expressed in the Declaration of Helsinki. This clinical trial is 
registered at clini caltr ials.gov (NCT01133158).
2.2 | Treatment and procedures
The RBMD regimen was designed based on modifications of 
two previously described regimens.19,21
Patients received the following treatment every 4 weeks: 
intravenous infusion of 375  mg/m2 rituximab on day 1; 
90 mg/m2 bendamustine on days 1 and 2; 6 mg/m2 mitoxan-
trone on day 1; and 20 mg oral dexamethasone on days 1‐5.
We used a response‐adapted approach to guide treatment 
intensity at induction. Patients with complete response/un-
confirmed complete response (CR/uCR) after three cycles of 
RBMD received a total of four cycles, whereas those with 
partial response (PR) received additional three cycles (six cy-
cles in total). Patients with stable disease/progressive disease 
(SD/PD) after the third or sixth cycle were withdrawn from 
the trial. Patients who achieved CR/uCR, or PR at the end of 
induction therapy (after four or six cycles) received rituximab 
maintenance (375 mg/m2) every 12 weeks for 2 years or until 
progression or unacceptable toxicity.
Participants underwent laboratory and clinical assessment 
before each treatment cycle, which they received only upon 
fulfilling the following criteria: absolute neutrophil count 
(ANC) >1.5  ×  109/L; platelet count  >75  ×  109/L; absence 
of toxic effects of grade 3 or higher. If grade 3/4 cytopenia 
was detected, the next cycle was delayed by 7‐14 days, and 
bendamustine treatment resumed at a reduced dose of 70 mg/
m2 for all subsequent cycles. If parameters did not return to 
baseline levels within 14 days, the cycle was delayed by a fur-
ther 14 days and bendamustine treatment resumed at a further 
reduced dose of 50 mg/m2 for the remaining cycles. If param-
eters failed to return to baseline levels after the second 14‐day 
delay, the patient was withdrawn from the trial. Reduction of 
the bendamustine dose to 70 and 50 mg/m2 was accompanied 
by a reduction in the mitoxantrone dose to 5 and 4 mg/m2, 
respectively. Treatment was discontinued if toxic effects were 
observed with the 50 mg/m2 dose of bendamustine. Rituximab 
dose reduction was not permitted. Escalation of the benda-
mustine dose after a dose reduction was not permitted.
Cycles were delayed for a maximum of 4  weeks in pa-
tients with grade 3/4 neutropenia. Longer delays resulted in 
withdrawal from the trial. Treatment was discontinued in 
cases of grade >3 nonhematologic adverse events (AEs) and 
grade 4 infections.
Patients with a lymphocyte count <1 × 109/L or a pre-
vious history of herpes virus infection received prophylaxis 
with co‐trimoxazole and acyclovir. Primary prophylaxis with 
G‐CSF and secondary prophylaxis or treatment in accordance 
with the American Society of Clinical Oncology Guidelines 
were permitted.22
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2.3 | Study objectives, response assessment, 
response criteria, and safety
The primary endpoint was CR/uCR after induction therapy 
(4‐6 cycles). Secondary endpoints were toxicity, the role of 
rituximab maintenance to prolong the response and delay the 
next treatment, OS and PFS.
Treatment response was assessed every 3 months during 
induction and maintenance treatment, every 6 months for the 
following 2 years, and then annually. Tumor assessment in-
cluded clinical assessment, physical examination, a routine 
laboratory test, and a CT scan. In patients in whom bone 
marrow infiltration was detected at staging, bone marrow 
biopsy was repeated in subsequent efficacy reassessments 
until confirmation of complete response in responding 
patients.
Patients were classified as CR, uCR, PR, SD, or PD 
according to the criteria of the National Cancer Institute 
International Working Group.23 PFS was defined as the time 
from the first dose of treatment to progression or tumor‐re-
lated death.
Patients who received at least one treatment cycle were in-
cluded in the toxicity analysis. AEs were monitored through-
out the study and graded according to the National Cancer 
Institute Common Terminology Criteria for AEs (v3.0).24
2.4 | Statistical analysis
Based on previous studies that reported an ORR of 50% after 
single agent rituximab, we selected a sample size of 60 patients 
to enable detection of a 20% increase in ORR after treatment 
with BR with a statistical power  >80% (using a two‐tailed 
analysis with significance set at 95%). Patients without at least 
one response assessment were considered nonresponders.
Continuous variables are represented as the mean, stan-
dard deviation, median, and range, and qualitative variables 
as absolute and relative frequencies (%) and corresponding 
95% confidence interval (95% CI).
A two‐sided 95% exact CI for ORR was calculated using 
the binomial distribution. The Kaplan‐Meier method was 
used to estimate median OS and PFS. Fisher's exact test was 
used for comparisons of independent groups. Significance 
was set at P < .05 for statistical analyses. SAS® 9.4 was used.
3 |  RESULTS
Sixty‐one patients were enrolled and assessed. After ex-
clusion of one screen failure, 60 patients (median age, 
62.5 years; range, 32‐76) received treatment according to 
the study protocol (Figure 1). These 60 patients had FL 
F I G U R E  1  Patient disposition. 
Patient disposition during induction therapy 
with RBMD. *1 patient who showed 
progressive disease during the first RBMD 
cycle died. **1 patient died due to grade 
5 infection (CMV reactivation in the 
context of influenza A sepsis). †8 patients 
were withdrawn due to toxicity, including 
five patients withdrawn due to treatment 
delays >4 wk. CR, complete response; 
PD, progressive disease; PR, partial 
response; RBMD, rituximab, bendamustine, 
mitoxantrone, and dexamethasone; SD, 
stable disease; uCR, unconfirmed complete 
response
Enrolled
N = 61
CR/uCR
N = 33
PD
N = 1
PR
N = 24
PD/SD
N = 2
PD
N = 2
Toxicity**
N = 1
PD
N = 1
Toxicity
N = 2
Toxicity†
N = 5
Any exclusion criteria
N = 2
Rituximab maintenance
N = 25 Rituximab maintenance
N = 18
(CR/uCR = 10; PR = 8)
Screening failure
N = 1
Early withdrawal
PD*
N = 1
Patients receiving
induction therapy
N = 60
Response assessment 
after 3 RBMD cycles
N = 59
Response assessment 
after 4 RBMD cycles
CR/uCR
N = 32
Response assessment 
after 6 RBMD cycles
CR/uCR
N = 10
PR
N = 11
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relapsed (n = 50) or refractory (n = 10) to first‐line rituxi-
mab‐containing immunotherapy and 43.3% (n  =  26) had 
received rituximab maintenance after first‐line therapy 
(Table 1, baseline characteristics in the intention‐to‐treat 
(ITT) analysis). None of the patients had received benda-
mustine in first‐line therapy.
Early response assessment revealed an ORR of 95% (95% 
CI, 86.1‐99.0): after the third cycle of RBMD, 55% of pa-
tients (33/60) achieved CR/uCR (CR‐3 group), 40% (24/60) 
achieved PR, and 5% (3/60) had PD/SD. Per protocol, 24 
patients who achieved PR after three cycles received a total 
of six treatment cycles (CR‐6 group). Of these, 10 (41.7%) 
subsequently achieved CR/uCR and 11 (45.8%) maintained 
PR. On completion of induction therapy (4‐6 cycles), 70% of 
patients were in CR or uCR and 18.3% in PR, for an ORR of 
88.3% (53/60 patients) (Table 2).
Seventeen patients (28.3%) were withdrawn from the 
trial before they could begin rituximab maintenance: seven 
were in PD/SD; two (both in CR) failed to fulfill the inclu-
sion criteria for starting maintenance therapy; and eight (5 
in CR/uCR, 3 in PR) due to toxicity. Forty‐three patients 
(71.7%) began rituximab maintenance: 25 in the CR‐3 
group and 18 in the CR‐6 group (10 in CR/uCR, 8 in PR) 
(Figure 1).
After 2  years of maintenance therapy, 32 patients were 
in CR/uCR, three in PR, and eight in PD (Table 2). In the 
CR‐3 subgroup, 65.6% (21/32) of patients maintained their 
response at the end of maintenance therapy. In the CR‐6 sub-
group, two patients in PR achieved CR during maintenance. 
During the maintenance therapy period, three patients were 
withdrawn from the trial due to protocol violation/deviations 
and another three due to toxicity. All six patients left the trial 
in CR.
With a median follow‐up of 28.3  months (95% CI, 
15.6‐51.2) after completion of rituximab maintenance, eight 
patients showed PD. Median PFS was 56.4 months (95% CI, 
28.3‐56.4), with 2‐ and 4‐year PFS probabilities of 73.4% 
(95% CI, 57.7‐84.0) and 52.9% (95% CI, 36.6‐66.7), re-
spectively (Figure 2A). Median overall survival (OS) was 
not reached; the 4‐year OS probability was 96.4% (95% CI, 
86.5‐99.1) (Figure 2B).
No differences in PFS were observed between the CR‐3 
subgroup, which showed an early response to RBMD (four 
cycles), and the group that received six cycles (P = .6665) 
(Figure 3). Similarly, PFS did not differ significantly be-
tween patients who did/did not receive rituximab mainte-
nance in first‐line therapy (median PFS, 42.3 months [95% 
CI, 15.6–NR] and 56.4 [95% CI, 25.5‐56.4], respectively; 
P  =  .5790) (Figure 4). However, PFS was significantly 
lower in patients refractory to first‐line therapy vs relapsed 
patients (median PFS, 25.5 months [95% CI, 0.6–NR] and 
56.4 months [95% CI, 39.0‐56.4], respectively; P = .0338). 
The 2‐year and 3‐year PFS probabilities in the refractory 
group were 52.5% (95% CI, 8.4‐84.6) and 26.3% (95% CI, 
1.1‐67.5), respectively (Figure 5). PFS patients who had 
shown progression of disease (POD) after 24  months of 
first‐line therapy had longer (median, 56.4  months [95% 
CI, 19.8‐56.4]) than those who showed POD after less than 
24  months of first‐line therapy (median, 42.31  months 
[95% CI, 24.41‐NA]), although this difference was not sta-
tistically significant (Figure 6).
4 |  SAFETY
All 60 patients who received RBMD were included in the 
safety analysis.
T A B L E  1  Baseline patient demographics and clinical 
characteristics at enrollment
N %
Patients 60
Age (y)
<60 26 43
>60 34 57
Sex
Female 30 50
Male 30 50
B symptoms
Present 10 17
Absent 50 83
Ann Arbor stage
I‐II 19 31.5
III‐IV 41 68.5
ECOG‐PS
0 38 63
1 21 35
2 1 2
FLIPI (number of risk factors)
Low (0‐1) 30 50
Intermediate (2) 17 28
High (3‐5) 13 22
First‐line treatment
R‐CHOP 43 71.7
R‐CVP 12 20
R‐FC 5 8.3
Rituximab maintenance after first‐line therapy 26 43.3
Note: Table shows data for 60 patients included in the intention‐to‐treat analysis. 
B symptoms refer to fever, weight loss >10%, and nights sweats.
Abbreviations: ECOG‐PS, Eastern Cooperative Oncology Group performance 
status; FLIPI, Follicular International Prognostic Index; R‐CHOP, rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone; R‐CVP, rituximab, 
cyclophosphamide, vincristine, and prednisone; R‐FC, rituximab, fludarabine, 
and cyclophosphamide.
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T A B L E  2  Response to RBMD
After three cycles
(N = 60)
At end of induction therapy (3‐6 cycles)
(N = 60)
To R‐maintenance therapy
(N = 43)
N % 95% CI N % 95% CI N % 95% CI
Complete responsea 33 55 41.61‐67.88 42 70 56.79‐81.85 32 74.5 58.83‐86.48
Partial response 24 40 27.56‐53.46 11 18.3 9.52‐30.44 3 7 1.46‐19.06
Overall response 57 95 86.08‐98.96 53 88.3 77.43‐95.18 35 81.5 66.60‐91.61
Stable disease 1 1.7 0.04‐8.94 1 1.7 0.04‐8.94
Progressive disease 2 3.3 0.41‐11.53 6 10 4.82‐22.57 8 18.5 8.39‐33.40
Abbreviations: CI, confidence interval; RBMD, rituximab, bendamustine, mitoxantrone, and dexamethasone.
aComplete response includes unconfirmed complete response. 
F I G U R E  2  Progression‐free survival (A) and overall survival (B) in patients who received RBMD plus rituximab maintenance therapy
56.4 (28.3, 56.4)65.0% (39)35.0% (21)60
Median (95% CI)CensoredEventNo. of Subjects
0 6 12 18 24 30 36 42 48 54
Pr
ob
ab
ili
ty
Progression-free survivalA
Months after study inclusion
0.50
0.25
0.00
0.75
1.00
0
Overall survival 
Pr
ob
ab
ili
ty
0.50
0.25
0.00
0.75
1.00
6 12 18 24 30 36 42 48 54 60
Months after study inclusion
NA (NA, NA)96.7% (58)3.3% (2)60
Median (95% CI)CensoredEventNo. of Subjects
B
F I G U R E  3  Progression‐free survival 
in patients with/without complete or 
unconfirmed complete response (CR/uCR) 
after three treatment cycles (CR‐3 vs CR‐6)
Progression-free survival 
Patients with CR/uCR 
after C3
Patients without CR/uCR 
after C3
+ Censored
Patients with CR/uCR after C3 vs.
Patients without CR/uCR after C3 (0.3426, 1.9846)0.8246
HR: 
P = .6665Long-Rank
Months after study inclusion
Patients with CR/uCR after C3 
Patients without CR/uCR after C3
NA (28.3, NA)
56.4 (12.9, 56.4)
69.7% (19)
59.3% (16)
30.3% (10)
40.7% (11)
33
27
Median (95% CI)CensoredEventNo. of subjects
0 6 12 18 24 30 36 42 48 54 60
0.00
0.25
0.50
0.75
1.00
Pr
ob
ab
ili
ty
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A total of 275 cycles of RBMD were administered (me-
dian and range per patient: 4, 1‐6). The number of chemother-
apy cycles per patient was <4 in eight patients (13.3%); four 
in 27 patients (45%); five in five patients (8.3%); and six in 20 
patients (33.3%). The bendamustine dose was reduced in 14 
patients, in all cases due to hematological toxicity. Forty‐four 
of the 275 (16%) cycles were delayed, due to hematological 
toxicity (28 [10.2%] cycles); nonhematological toxicity (3 
[1.1%] cycles); hematological and nonhematological toxicity 
(3 [1.1%] cycles); or other reasons (10 [3.6%] cycles).
Rituximab maintenance therapy was administered to 43 
patients (total number of doses: 286; median and range per 
patient: 8, 1‐10). Twenty‐six (60.5%) patients received the 
eight scheduled doses of rituximab. Rituximab maintenance 
was delayed in 10 of 43 (23.3%) patients due to hematologi-
cal toxicity (9.3%), nonhematological toxicity (2.3%), or non-
rituximab‐related toxicity (11.6%).
At least one grade 3/4 AE was observed in 53 of 60 (88.3%) 
patients during the induction phase and 24 of 43 (55.8%) pa-
tients during the maintenance phase. The most common grade 
F I G U R E  4  Progression‐free survival 
in patients who did/did not receive first‐line 
maintenance therapy
Progression-free survival 
Pr
ob
ab
ili
ty
Patients who did receive 
first-line maintenance therapy
Patients who did not receive first-line 
maintenance therapy
Patients who did receive first-line maintenance therapy vs
Patients who did not receive first-line maintenance therapy
Patients who did receive first-line maintenance therapy
Patients who did not receive first-line maintenance therapy
+ Censored
0.50
0.25
0.00
0.75
1.00
0 6 12 18 24 30 36 42 48 54
Months after study inclusion
(0.5327, 3.0814)1.2812
HR: 
P = .5790Long-Rank
42.3 (15.6, NA)
56.4 (25.5, 56.4)
61.5% (16)
67.6% (23)
38.5% (10)
32.4% (11)
26
34
Median (95% CI)CensoredEventNo. of subjects
F I G U R E  5  Progression‐free survival 
(relapsed vs refractory)
Progression-free survival 
Relapsed
Refractory
Relapsed yrotcarfeRderosneC +
Pr
ob
ab
ili
ty
0.50
0.25
0.00
0.75
1.00
Months since study inclusion
0 6 12 18 24 30 36 42 48 54
56.4 (39.0, 56.4)
25.5 (0.6, NA)
66.0% (33)
60.0% (6)
34.0% (17)
40.0% (4)
50
10
Median (95% CI)CensoredEventNo. of subjects
(1.0316, 9.5949)3.1461HR refractory vs relapsed
P = .0338Long-Rank
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3/4 toxicity was hematological (Table 3), including lympho-
penia (70%) and neutropenia (60%). The most frequent se-
vere toxicities during maintenance therapy were neutropenia 
(27.3%) and lymphopenia (25%). Febrile neutropenia was 
observed in only 6.7% (4/60) of patients during induction 
with RBMD and 4.5% (2/43) during rituximab maintenance.
During induction and before maintenance therapy, five 
(8.3%) patients were withdrawn from the trial due to a 
F I G U R E  6  Progression‐free survival 
according to progression of disease after 
first‐line immunochemotherapy (before/after 
24 mo of treatment) prior to enrollment in 
the trial
Pr
ob
ab
ili
ty
56.4 (19.8, 56.4)67.9% (19)32.1% (9)28POD after 24 months
42.3 (24.4, NA)62.5% (20)37.5% (12)32POD before 24 months
Median (CI 95%)CensoredEventNo. of subjects
0 6 12 18 24 30 36 42 48 54 60
0.00
0.25
0.50
0.75
1.00
(0.2844, 1.7051)0.6964HR: POD after 24 months vs POD before 24 months 
P = .4258Log-Rank
+ Censored POD before 24 months POD after 24 months
Months after study inclusion
Progression-free survival 
T A B L E  3  Adverse events observed in >2 patients who received at least one cycle of RBMD
Grades 1‐2 Grades 3‐4
RBMD (%) R‐maintenance (%) RBMD (%) R‐maintenance (%)
Hematological
Lymphopenia 12 (20) 25 (56.82) 42 (70) 11 (25)
Neutropenia 11 (18.3) 14 (31.8) 36 (60) 12 (27.3)
Anemia 38 (63.3) 17 (38.6) 1 (1.7) 1 (2.3)
Thrombocytopenia 34 (56.7) 14 (31.8) 2 (3.3) 1 (2.3)
Nonhematological
Fatigue 13 (21.7) 2 (4.5) 1 (1.7)
Infections 11 (18.3) 13 (27.5) 5 (8.3)a 4 (9.1)
Fever (nonneutropenic) 9 (15) 2 (4.5) 2 (3.3)
Vomiting 8 (13.3)
Infusion reactions 6 (10) 2 (3.3)
Constipation 5 (8.3)
Pain 5 (8.3) 4 (9.1)
Diarrhea 4 (6.7) 1 (1.7)
Nausea 3 (5)
Rash 3 (5) 1 (2.3)
Febrile neutropenia 4 (6.7) 2 (4.5)
Note: Adverse events recorded during induction and maintenance therapy in 60 patients who received at least one cycle of RBMD and were included in the toxicity 
analysis.
Abbreviations: RBMD, rituximab, bendamustine, mitoxantrone, and dexamethasone; R‐maintenance, rituximab maintenance therapy.
aOne patient had grade 5 infection and died from septic shock due to influenza A infection. 
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treatment cycle delay >4 weeks and three (5%) patients were 
drawn due to toxicity (severe infusion reaction, severe respi-
ratory infection, and septic shock associated with respiratory 
infection in the context of influenza A infection after the fifth 
RBMD cycle, resulting in death in CR). Five (8.3%) patients 
developed severe infections without neutropenia and one pa-
tient (with PD during the first cycle) died. During mainte-
nance therapy, three of 43 (7%) patients were withdrawn from 
the trial due to toxicity; specifically, a treatment cycle delay 
>4 weeks for recovery from neutropenia (n = 1); myelodys-
plastic syndrome (n = 1); and worsening performance status 
without relapse or infection (n = 1).
Granulocyte colony‐stimulating factor (G‐CSF) was ad-
ministered to 34 of 60 (56.6%) patients (median, 3 doses; 
range, 1‐6) either as prophylaxis or as treatment during the 
induction phase, and to nine of 43 (20.9%) patients during 
rituximab maintenance (median, 1 dose; range, 1‐5).
5 |  DISCUSSION
Our results indicate that RBMD therapy using a response‐
adapted strategy followed by rituximab maintenance is effec-
tive and safe in FL patients relapsed or refractory to first‐line 
immunochemotherapy, including those who previously re-
ceived rituximab maintenance after first‐line therapy.
Treatment of patients with relapsed or refractory FL, par-
ticularly those who have received immunochemotherapy with 
regimens such as R‐CHOP, R‐CVP, or R‐FCM, is becom-
ing increasingly difficult. RBMD is a new regimen for the 
treatment of these patients and this trial is the first specifi-
cally designed to assess this combination in a homogeneous 
population of FL patients previously treated with rituximab. 
We also evaluated the efficacy of rituximab maintenance in 
patients treated with regimens that included rituximab and 
bendamustine as salvage therapy.
The observed response rate (88.3%, including 70% 
CR and a median PFS of 56.4 months) is very promising, 
particularly given that less than 50% of patients received 
more than four cycles. Other regimens based on bendamus-
tine‐containing chemotherapy plus rituximab have been 
previously used to treat relapsed/refractory indolent lym-
phoma, and have achieved response rates comparable to 
those of RBMD, albeit mainly in rituximab‐naïve patients. 
A similar schema consisting of rituximab, bendamustine, 
and mitoxantrone was used to treat relapsed or refrac-
tory indolent and mantle cell lymphoma patients.19 That 
study, which included 29 patients with FL (38% previously 
treated with rituximab), reported an ORR of 92% (CR 50%) 
and a median PFS of 17 months. In patients treated with 
BR, ORR ranged from 93% to 96% and CR rates from 54% 
to 71%, but the median PFS was 23‐24 months (44‐100% 
rituximab‐naïve).12,13 The addition of bortezomib25 to BR 
resulted in an ORR of 88% (CR, 53%) and a median PFS 
of 14.9 months. In a randomized phase III trial comparing 
BR with FR in patients with relapsed indolent lymphoma 
(61% rituximab‐naïve), BR was significantly more effica-
cious (ORR, 82%; CR, 40%; median PFS, 34.2  months) 
than FR.14 In hard‐to‐treat rituximab‐refractory indolent 
lymphoma patients, bendamustine as monotherapy at a 
higher dose (120 mg/m2, days 1‐2) resulted in an ORR of 
77%‐80%, although the benefit was short‐lived (median 
PFS, 7‐9 months),26,27 and when combined with obinutu-
zumab18 resulted in higher minimal residual disease‐nega-
tive rates and improved efficacy and overall survival.
In recent years, novel therapies (eg, immunomodulatory 
therapies, PI3K inhibitors, BTK inhibitors, BLC2 inhibi-
tors) in monotherapy or combined with rituximab have 
been used to treat this population. High response rates have 
been reported for the immunomodulator lenalidomide and 
for PI3K inhibitors. The Augment study of 358 patients 
with relapsed indolent lymphoma (84% FL; median number 
of previous treatments, 1) reported an ORR of 78%, CR of 
34%, and a median PFS of 39.4 months after treatment with 
lenalidomide plus rituximab, although patients refractory 
to rituximab or rituximab combinations were excluded.28 
Based on the results of phase II studies, three PI3K inhib-
itors (idelalisib, copanlisib, and duvelisib) are currently 
available for the treatment of FL that has relapsed or is re-
fractory after two or more previous lines of therapy.29-31 
These studies, which included heavily treated FL patients, 
reported ORR rates of 56%, 59%, and 42%, respectively 
(with respective CR rates of 14%, 14%, and 1%), and me-
dian PFS ranging from 9.5 to 11 months. One of the main 
concerns with PI3K inhibitors is their potential toxicity, 
which can cause gastrointestinal, hepatic, and infectious 
complications. However, their high activity makes them 
a therapeutic option for high‐risk FL (particularly in pa-
tients with early progression or treatment failure for whom 
available strategies are unsatisfactory); in these situations 
PI3K inhibitors may provide a bridge to transplantation.32 
Comparatively poorer response rates have been reported 
for BTK inhibitors33 and BCL2 inhibitors.34,35
In our study, the median PFS in the 10 patients refractory 
to first‐line rituximab‐containing immunochemotherapy was 
25.5 months. The PFS obtained with RBMD followed by rit-
uximab maintenance in this subgroup of patients, over half of 
whom received only four cycles, is similar to that reported for 
obinutuzumab plus bendamustine followed by obinutuzumab 
maintenance (25.3 months),18 suggesting that RBMD may be 
a useful alternative if obinutuzumab is unavailable.
Two recent studies proposed that POD within 2 years of 
diagnosis in FL patients treated with first‐line immunochem-
otherapy is a predictor of poor outcome.15,36 Stratification of 
our patient population according to POD following first‐line 
therapy (before or after 24 months) revealed that the majority 
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(n  =  32, including the 10 refractory cases) corresponded 
to the former subgroup. We observed no significant differ-
ences in PFS between subgroups. Nonetheless, for patients 
who showed POD in less than 24  months the median PFS 
was 42.31 months, an acceptable response for patients who 
have a poor prognosis and are not candidates for intensive 
chemotherapy.
The EORTC 20891 trial demonstrated that in relapsed 
and refractory FL patients, rituximab maintenance improves 
PFS after CHOP and R‐CHOP (no patients had been previ-
ously treated with rituximab). At 6‐year follow‐up, the me-
dian PFS after induction for patients in CR was 52.8 months 
in the rituximab maintenance arm, vs 14.4  months in the 
observation arm.10 However, data on the efficacy of ritux-
imab maintenance in relapsed patients who have responded 
to BR schedules are scarce. Currently, most patients receive 
rituximab maintenance after first‐line therapy. We hypoth-
esize that after achieving a response with RBMD rescue 
treatment, the duration of the response can be prolonged 
with rituximab maintenance. Compared with other stud-
ies of bendamustine‐containing chemotherapy plus rit-
uximab, in which the majority of patients was not treated 
with rituximab and did not receive rituximab maintenance 
therapy, our results show that rituximab maintenance im-
proves PFS after rescue with RBMD, with no significant 
differences between patients who did/did not receive rit-
uximab maintenance after first‐line therapy. The median 
PFS in this trial, in which all patients had been previously 
exposed to rituximab, was 56.4  months. This outcome is 
superior to those reported for bendamustine‐containing 
combinations without rituximab maintenance (median 
PFS, 17‐24  months).12,13,19 A German phase III trial that 
included a small subgroup of patients who received ritux-
imab maintenance after response to BR reported a median 
PFS of 72.1 months, although two‐thirds of the cases were 
rituximab‐naïve.14 However, these trials included heteroge-
neous populations of patients, precluding accurate compar-
ison of study outcomes. In current practice, all relapsed/
refractory FL patients would have been previously exposed 
to rituximab during induction and/or maintenance therapy. 
We found no significant differences in PFS between pa-
tients who did/did not receive prior rituximab maintenance 
after first‐line therapy. While data on the usefulness of sec-
ond rituximab maintenance are scarce,20 the median PFS of 
42.3 months reported here suggests that second rituximab 
maintenance is a reasonable strategy in responding patients. 
In conclusion, our results show that rituximab maintenance 
improves PFS after rescue with RBMD, with no significant 
differences between patients who did/did not receive ritux-
imab maintenance after first‐line therapy.
In our study, 55% of patients achieved CR/uCR after 
only three cycles of RBMD. Furthermore, two patients 
with PR after six RBMD cycles achieved CR during 
maintenance with rituximab. After rituximab maintenance, 
no differences in PFS were observed between the CR‐3 and 
CR‐6 subgroups. These results suggest that patients treated 
with RBMD can achieve CR with fewer cycles and identify 
a subset of patients who may require less rescue treatment.
Overall, dose‐adapted RBMD was well tolerated, with a 
safety profile similar to that reported for BR.37 Rituximab 
maintenance resulted in no unexpected toxicity. The most 
common toxicity during induction and maintenance was he-
matological (grade 3/4 neutropenia in 60% of patients), but 
did not translate into an increase in the number of patients 
with febrile neutropenia or infections. One patient developed 
an opportunistic infection due to CMV reactivation in the 
context of influenza A sepsis, and ultimately died. Fatigue 
was the most common nonhematological toxicity, which was 
tolerable. Only four cases of skin rash were recorded, likely 
due to the inclusion of dexamethasone in the regimen. A pre-
vious phase II trial of bendamustine and mitoxantrone plus 
rituximab in patients with untreated high‐risk FL was pre-
maturely closed due to severe hematological and infectious 
toxicities and second malignancies.38 In our trial, in which 
all patients had received previous immunochemotherapy, we 
observed no severe toxicities and only one diagnosis of myel-
odysplastic syndrome. Our response‐adapted strategy, which 
limited immunochemotherapy to only four cycles in over half 
of all cases, together with the low dose of mitoxantrone and 
the early withdrawal of patients with sustained myelotoxicity, 
likely contributed to favorable tolerability. The use of G‐CSF 
and mandatory anti‐infective prophylaxis with co‐trimox-
azole and acyclovir may also have made this regimen safer. 
Recent data from a phase III trial have raised concerns about 
the toxicity profile of bendamustine with rituximab or obinu-
tuzumab followed by anti‐CD20 maintenance in first‐line 
treatment of FL.39 However, acceptable toxicity was reported 
in two recent phase III trials of induction therapy with BR 
followed by rituximab maintenance.40,41 Additional studies 
with longer follow‐up periods will be required to better char-
acterize the toxicity profile of this drug combination.
Limitations of our study include the small sample size of 
the refractory patient subgroup, the lack of a comparator group, 
and the fact that response evaluation was based on assessments 
made by local investigators. Moreover, some of the studies 
with which we have compared our findings included ritux-
imab‐naïve patients with indolent and mantle cell lymphoma.
In summary, in patients with relapsed/refractory FL 
after first‐line immunochemotherapy, RBMD salvage ther-
apy using a response‐adapted strategy followed by ritux-
imab maintenance is effective, has an acceptable safety 
profile, and allows for a reduced induction therapy, thereby 
improving tolerability without compromising efficacy. This 
regimen could constitute an alternative salvage regimen for 
patients treated with other rituximab‐containing combina-
tions plus rituximab maintenance in first‐line therapy.
   | 6965PEÑALVER Et AL.
ACKNOWLEDGMENTS
We thank the patients and their families who participated 
in this study as well as the other members of GELTAMO 
working at participating centers, without whom this study 
would not have been possible: José Luis Bello López (HU 
de Santiago de Compostela), Félix Carbonell (HGU de 
Valencia), Secundino Ferrer Bordás (HU Doctor Peset, 
Valencia), Patricia Font López (HU Gregorio Marañón, 
Madrid), Ernesto Pérez Persona (Hospital Txagorritxu, 
Vitoria‐Gasteiz), Armando López Guillermo (Hospital 
Clínic de Barcelona), Roberto Hernández Martín (Hospital 
Virgen de la Concha, Zamora), José Ramón Mayans (HU 
Arnau de Vilanova, Lleida), Luis Palomera (HCU Lozano 
Blesa, Zaragoza), Elena Pérez Ceballos (HGU Morales 
Meseguer, Murcia), José Antonio Queizán Hernández 
(Hospital General de Segovia), Rosalía Riaza Grau (HU 
Severo Ochoa, Leganés), Fátima de la Cruz (HU Virgen 
del Rocío, Sevilla), and Andrés Sánchez Salinas (HCU 
Virgen de la Arrixaca, Murcia). Thanks also to Adelaida 
Velasco and Owen Howard for editorial assistance, and Ana 
Drozdowskyj for assistance with the statistical analyses. 
Finally, thanks to Yago Parga for his continued support of 
this project.
CONFLICT OF INTEREST
The authors declare no potential conflict of interest.
AUTHOR CONTRIBUTIONS
Francisco‐Javier Peñalver: Study concept, study design, 
enrollment of patients, data collection, data analysis, study 
oversight, manuscript writing, and approval of final manu-
script. José‐Antonio Márquez, Soledad Durán, Pilar Giraldo, 
Alejandro Martín, Carlos Montalbán, María‐José Ramírez, 
María‐José Terol, Francisco‐Javier Capote, Antonio 
Gutiérrez, and Blanca Sánchez: Enrollment of patients, 
data collection and analysis, and approval of final manu-
script. Juan‐Manuel Sancho, Andrés López and Antonio 
Salar: Enrollment of patients, data collection, data analysis, 
manuscript writing, and approval of final manuscript. Gil 
Rodríguez‐Caravaca: data analysis, study oversight, and 
approval of final manuscript. Miguel Canales: Study de-
sign, enrollment of patients, data collection, data analysis, 
and approval of final manuscript, María‐Dolores Caballero: 
Study design, study oversight, funding, and approval of final 
manuscript.
ORCID
Antonio Gutiérrez   https://orcid.org/0000-0001-9062-077X 
Antonio Salar   https://orcid.org/0000-0002-4652-4825 
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available 
on request from the corresponding author. The data are not 
publicly available due to privacy or ethical restrictions.
REFERENCES
 1. Hiddemann W, Cheson BD. How we manage follicular lymphoma. 
Leukemia. 2014;28(7):1388‐1395.
 2. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic 
strategies. Blood. 2016;127(17):2055‐2063.
 3. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with 
rituximab added to the combination of cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (CHOP) significantly improves 
the outcome for patients with advanced‐stage follicular lymphoma 
compared with therapy with CHOP alone: results of a prospective 
randomized study of the German Low-Grade Lymphoma Study 
Group. Blood. 2005;106(12):3725‐3732.
 4. Marcus R, Imrie K, Solal‐Celigny P, et al. Phase III study of R‐
CVP compared with cyclophosphamide, vincristine, and predni-
sone alone in patients with previously untreated advanced follicular 
lymphoma. J Clin Oncol. 2008;26(28):4579‐4586.
 5. Herold M, Haas A, Srock S, et al. Rituximab added to first‐line mitox-
antrone, chlorambucil, and prednisolone chemotherapy followed by 
interferon maintenance prolongs survival in patients with advanced 
follicular lymphoma: an East German Study Group Hematology and 
Oncology Study. J Clin Oncol. 2007;25(15):1986‐1992.
 6. Salles G, Mounier N, de Guibert S, et al. Rituximab combined 
with chemotherapy and interferon in follicular lymphoma pa-
tients: results of the GELA‐GOELAMS FL2000 study. Blood. 
2008;112(13):4824‐4831.
 7. Luminari S, Ferrari A, Manni M, et al. Long‐term results of the 
FOLL05 trial comparing R‐CVP versus R‐CHOP versus R‐FM for 
the initial treatment of patients with advanced‐stage symptomatic 
follicular lymphoma. J Clin Oncol. 2018;36(7):689‐696.
 8. Salles G, Seymour JF, Feugier P, et al. Long term follow‐up of the 
PRIMA study: half of patients receiving rituximab maintenance re-
main progression free at 10 years. Blood. 2017;130(Suppl 1):486.
 9. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab 
to a combination of fludarabine, cyclophosphamide, mitoxantrone 
(FCM) significantly increases the response rate and prolongs survival 
as compared with FCM alone in patients with relapsed and refractory 
follicular and mantle cell. Blood. 2004;104(10):3064‐3071.
 10. van Oers M, Van Glabbeke M, Giurgea L, et al. Rituximab 
maintenance treatment of relapsed/resistant follicular non‐
Hodgkin's lymphoma: long‐term outcome of the EORTC 
20981 phase III randomized intergroup study. J Clin Oncol. 
2010;28(17):2853‐2858.
 11. López‐Guillermo A, Caballero D, Canales M, Provencio M, Rueda 
A, Salar A. Clinical practice guidelines for first‐line/after‐relapse 
treatment of patients with follicular lymphoma. Leuk Lymphoma. 
2011;52(sup3):1‐14.
 12. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II mul-
ticenter study of bendamustine plus rituximab in patients with re-
lapsed indolent B‐cell and mantle cell non‐Hodgkin's lymphoma. J 
Clin Oncol. 2008;26(27):4473‐4479.
 13. Rummel MJ, Al‐Batran SE, Kim S‐Z, et al. Bendamustine plus 
rituximab is effective and has a favorable toxicity profile in the 
6966 |   PEÑALVER Et AL.
treatment of mantle cell and low‐grade non‐Hodgkin's lymphoma. 
J Clin Oncol. 2005;23(15):3383‐3389.
 14. Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab 
versus fludarabine plus rituximab for patients with relapsed indo-
lent and mantle‐cell lymphomas: a multicentre, randomised, open‐
label, non‐inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57‐66.
 15. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular 
lymphoma after rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisone defines patients at high risk for death: 
an analysis from the National LymphoCare Study. J Clin Oncol. 
2015;33(23):2516‐2522.
 16. Mozessohn L, Cheung MC, Crump M, et al. Chemoimmunotherapy 
resistant follicular lymphoma: predictors of resistance, association with 
transformation and prognosis. Leuk Lymphoma. 2014;55(11):2502‐2507.
 17. Sorigue M, Sancho J‐M, Mercadal S, et al. Prevalence, predictive fac-
tors therapy and outcome of patients with follicular lymphoma refrac-
tory to first line immunochemotherapy. Blood. 2015;126(23):1510.
 18. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamus-
tine versus bendamustine monotherapy in patients with ritux-
imab‐refractory indolent non‐Hodgkin lymphoma (GADOLIN): 
a randomised, controlled, open‐label, multicentre, phase 3 trial. 
Lancet Oncol. 2016;17(8):1081‐1093.
 19. Weide R, Hess G, Köppler H, et al. High anti‐lymphoma activity of 
bendamustine/mitoxantrone/rituximab in rituximab pretreated re-
lapsed or refractory indolent lymphomas and mantle cell lymphomas. 
A multicenter phase II study of the German Low Grade Lymphoma 
Study Group (GLSG). Leuk Lymphoma. 2007;48(7):1299‐1306.
 20. Sanchez‐Gonzalez B, Gimeno E, Garcia‐Pallarols F, Ancochea 
A, Salar A. Usefulness of second rituximab maintenance after re-
lapse in patients with follicular and mantle cell lymphoma. Leuk 
Lymphoma. 2014;55(10):2384‐2386.
 21. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, 
mitoxantrone, and dexamethasone: an effective new regimen for 
indolent lymphoma. J Clin Oncol. 1996;14(4):1262‐1268.
 22. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of 
WBC growth factors: American Society of Clinical Oncology Clinical 
Practice Guideline Update. J Clin Oncol. 2015;33(28):3199‐3212.
 23. Cheson BD, Horning SJ, Coiffier B, et al. Report of an interna-
tional workshop to standardize response criteria for non‐Hodgkin's 
lymphomas. J Clin Oncol. 1999;17(4):1244‐1253.
 24. Cancer Therapy Evaluation Program. Common terminology cri-
teria for adverse events v3.0 (CTCAE). https ://ctep.cancer.gov/
proto colDe velop ment/elect ronic_appli catio ns/docs/ctcae v3.pdf. 
Published 2006. Accessed June 13, 2019.
 25. Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rit-
uximab in patients with relapsed or refractory follicular lymphoma: 
The phase II vertical study. J Clin Oncol. 2011;29(25):3389‐3395.
 26. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients 
with rituximab‐refractory indolent and transformed non‐Hodgkin's 
lymphoma: results from a phase II multicenter, single‐agent study. 
J Clin Oncol. 2008;26(2):204‐210.
 27. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effec-
tive therapy in patients with rituximab‐refractory, indolent B‐cell 
non‐Hodgkin lymphoma: results from a multicenter study. Cancer. 
2010;116(1):106‐114.
 28. Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III 
study of lenalidomide plus rituximab versus placebo plus ritux-
imab in relapsed or refractory indolent lymphoma. J Clin Oncol. 
2019;37(14):1188‐1199.
 29. Salles G, Schuster SJ, de Vos S, et al. Efficacy and safety of ide-
lalisib in patients with relapsed, rituximab‐ and alkylating agent‐
refractory follicular lymphoma: a subgroup analysis of a phase 2 
study. Haematologica. 2017;102(4):e156‐e159.
 30. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3‐
kinase inhibition by copanlisib in relapsed or refractory indolent 
lymphoma. J Clin Oncol. 2017;35(35):3898‐3905.
 31. Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II 
study of duvelisib (IPI‐145) in patients with refractory indolent 
non‐Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912‐922.
 32. Sorigue M, Sancho J‐M. Recent landmark studies in follicular lym-
phoma. Blood Rev. 2019;35:68‐80.
 33. Fowler N, Boyd TE, Sharman JP, et al. Long‐term follow‐up and 
analysis of dose groups with ibrutinib in relapsed follicular lym-
phoma. Blood. 2015;126(23):2706.
 34. Gerecitano JF, Roberts AW, Seymour JF, et al. A phase 1 study of vene-
toclax (ABT‐199 / GDC‐0199) monotherapy in patients with relapsed/
refractory non‐Hodgkin lymphoma. Blood. 2015;126(23):254.
 35. de Vos S, Swinnen L, Kozloff M, et al. A dose‐escalation study 
of venetoclax (ABT‐199/GDC‐0199) in combination with benda-
mustine and rituximab in patients with relapsed or refractory non‐
Hodgkin's lymphoma. Blood. 2015;126(23):255.
 36. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and 
relative survival in follicular grade 1–2 lymphoma during 4 decades: 
the Stanford University experience. Blood. 2013;122(6):981‐987.
 37. Peñalver FJ, Delgado J, Loscertales J, et al. Recommendations on 
the clinical use of bendamustine in lymphoproliferative syndromes 
and multiple myeloma. Eur J Haematol. 2016;96(5):532‐540.
 38. Cheah CY, Nastoupil LJ, McLaughlin P, et al. Premature closure of a 
phase II study of bendamustine, mitoxantrone and rituximab for patients 
with untreated high‐risk follicular lymphoma due to severe haemato-
logical and infectious toxicity. Br J Haematol. 2016;175(3):531‐533.
 39. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the 
first‐line treatment of follicular lymphoma. N Engl J Med. 
2017;377(14):1331‐1344.
 40. Rummel MJ, Buske C, Hertenstein B, et al. Four versus two years 
of rituximab maintenance (R‐maintenance) following bendamustine 
plus rituximab (B‐R): initial results of a prospective, randomized 
multicenter phase 3 study in first‐line follicular lymphoma (the StiL 
NHL7‐2008 MAINTAIN study). Blood. 2017;130(Suppl 1):483.
 41. Kahl BS, Burke JM, van der Jagt R, et al. Assessment of mainte-
nance rituximab after first‐line bendamustine‐rituximab in patients 
with follicular lymphoma: an analysis from the BRIGHT trial. 
Blood. 2017;130(Suppl 1):484.
How to cite this article: Peñalver F‐J, Márquez J‐A, 
Durán S, et al; on behalf of GELTAMO (The Spanish 
Lymphoma Cooperative Group). Response‐adapted 
treatment with rituximab, bendamustine, 
mitoxantrone, and dexamethasone followed by 
rituximab maintenance in patients with relapsed or 
refractory follicular lymphoma after first‐line 
immunochemotherapy: Results of the 
RBMDGELTAMO08 phase II trial. Cancer Med. 
2019;8:6955–6966. https ://doi.org/10.1002/cam4.2555
